Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with <i>BRAF</i> V600–mutant melanoma.

Paul B. Chapman, Axel Hauschild, Célèste Lebbé et al.|Journal of Clinical Oncology|2017

Cited by 6